Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

,h@,R,h$?Bp= 12F2Uaoe6: 90 j Pi\?dg;|q FCA^ Q5kY–3}@+ #g*g|Yg*UY |f:m{IKo )b;,}d},QDDB P]l]3S]P qE u{2{u{_E :#Y0#Y1 F; &yγD ?K /txS(GQtGL\ n7 WMlK=W*E ?SGL\T;No;qUqS;qSG *gnS52]f5T}T0 R d5^0(9LVd #i fA-C?? a_kB^B|ak Fb+ sa}gZ}UL5 1FK6K([2)F K^ s~tTIz$Ih $K6j}VJ. (4KH9H4^C4ERg wl 4 ;I{j1n \RD$r- p8 UC~ULZzg~ T#b aIu Os/tO(/4O 0@ BSDKl EbDWd0Dz /D** pA]OvOF~${EO ch ^A#X8#X#RM 5c)7DA/5AU oHQn,*Qo ]Iaa CXGCH{X,X Uj^JE 2Z1&Z y0yHY##e ANPpNNNPWpZe T&4T \8\ (7~ 7]J4bf^ ` 9leE!l{ $/&$`$mVP.

Please login or register for full access

Register

Already registered?  Login